AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03504501
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral application prior to transcranial magnetic stimulation intervention
Trial: NCT02675660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules once daily
Trial: NCT00509275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01935778
Drug: Docetaxel and capecitabine and oxaliplatin
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Docetaxel 60 mg/m² IV Day 1 Capecitabine 800 mg/m² bid (Day 1-Day 14) Oxaliplatin 100 mg/m² IV Day 1
Trial: NCT01935778
Drug: capecitabine and oxaliplatin
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
Trial: NCT02648919
Drug: Noni extract
RxNorm normalized name: noni fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention will be administered on an outpatient basis.Six bottles containing 60 capsules will be dispensed to all participants upon enrollment. Then 12 bottles (at 30-day visit) and 18 bottles (at 3, 6 and 9 month visits) will be dispensed to all participants.
Trial: NCT00544570
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02928965
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules containing 100mg minocycline (modified release), administered orally by the patient, two per day for the first two weeks and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.
Trial: NCT02928965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo with appearance of over - encapsulated minocycline
Trial: NCT00544778
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01834989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01939613
Drug: colloids
RxNorm normalized name: Technetium (99mTc), particles and colloids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMMU group allows for administration of colloids early,while Parkland group infuse colloids 24 h after burn injury.
Trial: NCT00832299
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of neo-adjuvant mFOLFOX6
Trial: NCT04456673
Drug: Inhaled Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Trial: NCT04456673
Drug: Inhaled Long-Acting Beta Agonist
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Trial: NCT04456673
Drug: Inhaled Long-Acting Muscarinic Antagonist
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation
Trial: NCT04456673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous
Trial: NCT02741739
Drug: REGN1033
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04382040
Drug: ArtemiC
RxNorm normalized name: ARTEMISININ 0.6 g in 100 g / CURCUMIN 2 g in 100 g / ASCORBIC ACID 6 g in 100 g / BOSWELLIA SACRA BARK 1.5 g in 100 g ORAL SPRAY, SUSPENSION [ArtemiC Rescue]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
Trial: NCT04382040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will be sprayed orally twice a day for the first 2 days in the treatment period
Trial: NCT03739268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo powder dissolved in water 1,600 mg three times a day for 17 days
Trial: NCT01096875
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1tb/day once daily for two weeks prior to surgery
Trial: NCT00401310
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV infusions 1hr/daily over 7 days.
Trial: NCT00822185
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg
Trial: NCT00822185
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg
Trial: NCT01916954
Drug: 3-day artemether-lumefantrine
RxNorm normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01916954
Drug: 5-day artemether-lumefantrine
RxNorm normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02007798
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml per bag
Trial: NCT04647773
Drug: HSK16149 20mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK16149 20mg, orally twice a day, treatment period; 13-weeks fixed dose.
Trial: NCT02382432
Drug: Pethidine 0.4mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2ml intravenous bolus slowly injected in 2minutes.
Trial: NCT04647773
Drug: HSK16149 40mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK16149 40mg, orally twice a day, treatment period; 13-weeks fixed dose.
Trial: NCT04647773
Drug: HSK16149 80mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK16149 80mg, orally twice a day, treatment period; 1-week titration and 12-weeks fixed dose.
Trial: NCT04647773
Drug: Placebo BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, orally twice a day, treatment period; 13-weeks fixed dose.
Trial: NCT00942604
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two day treatment
Trial: NCT00553891
Drug: placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One spray in each nostril once daily for 3 months.
Trial: NCT01143246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11 mg mannitol reconstituted with 5 ml of sterile 0.9% sodium chloride solution.
Trial: NCT00161148
Drug: Probiotics
RxNorm normalized name: probiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01077908
Drug: Best available antiviral drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Intravenous ganciclovir 5mg/kg twice daily~2. Oral valganciclovir 900mg twice daily~3. Intravenous foscarnet 90 mg/kg twice daily
Trial: NCT04163419
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 mg SC
Trial: NCT02129439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention of placebo-treated subjects does not vary to SB012-treated subjects.~The treatment phase lasts 28 consecutive days. Placebo will be administered for the first time at the study site in the morning on Day 1 (Administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP/Placebo will be self-administered by the subject at home. Placebo will be administered with a volume of 30ml.~The IMP/Placebo is formulated as an enema (plastic rectal tube) and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.
Trial: NCT02992743
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Trial: NCT00017108
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03636503
Drug: PF04518600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40
Trial: NCT00381680
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00381680
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT or IV
Trial: NCT00381680
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00381680
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT02222623
Drug: NPH
RxNorm normalized name: ZENPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH 2/3 of the total daily dose given with breakfast, 1/3 of the total daily dose given at bedtime. The initial dose is calculated using the patient's weight or using the basal insulin dose prior to hospitalization.
Trial: NCT00381680
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01884467
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of Gentamicin versus placebo
Trial: NCT01884467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01934101
Drug: CHR-5154
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHR-5154
Trial: NCT01934101
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01012765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to indacaterol o.d. delivered via SDDPI
Trial: NCT02852876
Drug: ASP2151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02852876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01651156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02071823
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of 50 mg (2 x 25 mg capsules) was administered in the morning of each study period under fasting or fed conditions. The two single dose administrations were separated by a wash-out of 7 days.
Trial: NCT01143129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution in a comparable amount to the experimental drug (0.05 mL/kg)
Trial: NCT00145795
Drug: Current Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00570492
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray
Trial: NCT04202601
Drug: IBI310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms 1: Neoadjuvant therapy group, 20 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Perioperative Sintilimab+ IBI310 are administered for 1-3 (6-18 weeks) cycles followed by 4 postoperative cycles (12 weeks) with Sintilimab monotherapy .~Arms 2: first-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.~Arms 3: ≥second-line therapy group, 30 patients Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion. Intervention：Sintilimab + IBI310 are administered for 1-3 (6-18 weeks) cycles followed by Sintilimab monotherapy for up to 2 years.
Trial: NCT00830726
Drug: Pharmacologic and mechanical heart failure treatment
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
Trial: NCT01099176
Drug: To compare monotherapies and combined therapy with each other
RxNorm normalized name: Other cardiac therapy combination products in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient received two tablets per day. Time interval between pills - 12 hours.~In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets
Trial: NCT00003401
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00044616
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01695707
Drug: Placebo (for pioglitazone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see Arm Description
Trial: NCT01437657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching RO4917523 placebo orally daily, 6 weeks
Trial: NCT01437657
Drug: RO4917523 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg orally daily, 6 weeks
Trial: NCT01437657
Drug: RO4917523 1.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg orally daily, 6 weeks
Trial: NCT00059462
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART alone
Trial: NCT00434291
Drug: TG-873870(Nemonoxacin)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01094847
Drug: DWJ1252
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet(oral) administration following the schedule of each arm
Trial: NCT02354898
Drug: BBI503
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03223961
Drug: EPREX
RxNorm normalized name: Eprex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 000 U/week for at least 12 weeks
Trial: NCT01804400
Drug: QAW039
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01804400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01587716
Drug: GSK2339345 (Inhaled) Single Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250, 1000 and 2000 microgram (proposed doses)
Trial: NCT01955824
Drug: 1% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01955824
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03332225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Placebo
Trial: NCT01093157
Drug: Adrenocorticotrophic hormone ACTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be two arms to the study: one arm receive 40 units and the second arm 80 units of the ACTH gel subcutaneously both given in a dose escalating frequency beginning at once every two weeks escalating to a maximum of twice per week over a total of three months exposed.An ammendment(approved by Health Canada and the UHN IRB allows an additional 1 month of the perscribed therapy of ACTH )if there is an improvement in proteinuria at the end of the 3 month exposure.
Trial: NCT01626469
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03644966
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women
Trial: NCT03549182
Drug: ATD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of ATD (100g)(Acute Tryptophan Depletion)
Trial: NCT03549182
Drug: placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of placebo (102.3g)
Trial: NCT00100269
Drug: Menevit anti-oxidant
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02839200
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching ACT-541468 capsules
Trial: NCT02839200
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching over-encapsulated zolpidem
Trial: NCT03666494
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As part of the patient's anesthetic induction, they will receive fentanyl.
Trial: NCT00986765
Drug: Lovenox® (enoxaparin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable solution 4000 UI
Trial: NCT00986765
Drug: Aspegic ® (Aspirin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day
Trial: NCT02077452
Drug: HMS5552
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02077452
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02874378
Drug: 0.9%NaCl solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02543918
Drug: Boostrix®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IM injection
Trial: NCT00975000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally following the same dosing regimen as the experimental arm.
Trial: NCT01869959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00503763
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00110448
Drug: No aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No aspirin use
Trial: NCT00380783
Drug: AGN 203818
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03728101
Drug: Simvastatin, Dabigatran Etexilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects receive dabigatran etexilate with and without simvastatin administration
Trial: NCT01817764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
Trial: NCT00041561
Drug: inhaled nitric oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled nitric oxide will be given at 5 ppm until day 28 or extubation
Trial: NCT02926833
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT03561480
Drug: 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight \<50 Kg.
Trial: NCT00329433
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
Trial: NCT01246193
Drug: CKD-828(FDC)
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
Trial: NCT02046551
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04085354
Drug: Dapoxetine and folic acid.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
Trial: NCT00444028
Drug: inhaled Placebo (0 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single placebo dose of inhaled loxapine
Trial: NCT01578486
Drug: salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: open-label trial of salsalate 3g/day for 12 weeks.
Trial: NCT04292899
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care Treatment for COVID-19 Infection
Trial: NCT00003576
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01714726
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 iv infusion on Week 0 and Week 4
Trial: NCT01497223
Drug: MGCD290
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Oral Dose Administration
Trial: NCT01846442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.